Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCirata Regulatory News (CRTA)

Share Price Information for Cirata (CRTA)

Share Price is delayed by 15 minutes
Get Live Data
16.95    -0.55 (-3.14%)
Bid:
16.80
Ask:
16.95
Spread: 0.15 (0.893%)
Market Cap: £21.42m
CRTA Live PriceLast checked at - London Stock Exchange

Intraday Cirata Share Chart

Grant of Awards & PDMR Dealing

12 Sep 2025 11:02

RNS Number : 1700Z
Cirata PLC
12 September 2025
Β 

12 September 2025

Β 

Cirata plc

("Cirata" or the "Company")

Grant of Awards & PDMR Dealing

Β 

Cirata (LSE: CRTA), announces a grant of awards to Stephen Kelly, Chief Executive Officer, under the Company's Share Options Plan (as amended and restated) ("SOP") (the "Award").

Β 

The Company's Remuneration Committee has approved the Awards and regards long term incentives as an important part of the remuneration of members of the leadership team to align them with shareholder interests.

Β 

Β 

Award Details

The Awards shall be structured in the form of equity-based payments. The Award is comprised of 50% share options and 50% performance-based share options. Each performance-based share option entitles the holder to receive one ordinary share of 10p each in the Company ("Ordinary Shares") upon vesting, subject to the achievement of the performance-based conditions detailed below.

Β 

Β· Options over 850,000 Ordinary Shares have been awarded which will vest at the end of June 2027 with an exercise price of 10 pence per share, being the nominal value of the shares on the grant date. This vesting will be subject to the achievement of a closing market price of the Company's Ordinary shares of at least 75 pence on the vesting date.

Β 

Β· Options over 850,000 Ordinary Shares have been awarded which will vest on a quarterly basis to the end of June 2027 with an exercise price of 22 pence per share. The options carry no performance conditions. Β 

Β 

Β 

In addition

Β 

Β· Options over 700,000 Ordinary Shares have been awarded which will vest on a quarterly basis through to the end of June 2027 with an exercise price of 22 pence per share. The options carry no performance conditions. This grant replaces a prior award, which has now been retired (as detailed below).

Β 

The Option strike price of 22[1] pence has been determined as the 60-day volume weighted average price to 9 September 2025.

Β 

Any shares issued upon exercise or vesting will rank pari passu with the existing Ordinary Shares of the Company. The Awards are subject to continued service and applicable malus and clawback provisions.

Retirement of Prior Award

Options over 700,000 Ordinary Shares with an exercise price of 86 pence per Ordinary Share, originally awarded to Stephen Kelly upon his appointment to the Company's board of directors on 10 May 2023, have been cancelled and replaced by the SOP Award.

Β 

Β 

The Awards to Stephen Kelly are summarised in the following schedule.Β 

Β 

Β 

Option Grants

Β 

Award

Number of Options

Total Options held post award

% of Issued Share capital[2]

Strike

Vesting Conditions

Vesting Date

Options

850,000

850,000

0.67%

Nominal Value (10 pence per share)

Closing price of Ordinary Shares of at least 75 pence on vesting date

End of June 2027

Options

850,000

850,000

0.67%

22 pence

None

Quarterly to end June 2027

Options

700,000

700,000

0.55%

22 pence

None

Quarterly to end June 2027

Β 

Β 

Following the grant of the Awards, Stephen Kelly is beneficially interested in 2,400,000 options over Ordinary Shares in the Company.

Β 

In addition, Stephen Kelly is the beneficial owner of 1,802,660 Ordinary Shares, representing 1.43% of the Company's total issued share capital.Β 

Β 

Β 

For further information, please contact:Β 

Β 

Cirata

Via FTI Consulting

Stephen Kelly, Chief Executive Officer

Ricardo Moura, Chief Financial Officer

Daniel Hayes, Investor Relations

FTI Consulting

+44 (0)20 3727 1137

Matt Dixon / Kwaku Aning / Usama Ali

Stifel (Nomad and Joint Broker)

+44 (0)20 7710 7600

Fred Walsh / Brough Ransom / Ben Good

Panmure Liberum (Joint Broker)

+44 (0)20 3100 2000

Max Jones / John More

Β 

Β 

About Cirata

Β 

Cirata, accelerates data-driven revenue growth by automating data transfer and integration to modern cloud analytics and AI platforms without downtime or disruption. With Cirata, data leaders can leverage the power of AI and analytics across their entire enterprise data estate to freely choose analytics technologies, avoid vendor, platform, or cloud lock-in while making AI and analytics faster, cheaper, and more flexible. Cirata's portfolio of products and technology solutions make strategic adoption of modern data analytics efficient and automated. For more information aboutΒ Cirata, visitΒ www.cirata.com

Β 

The relevant notifications set out below are provided in accordance with the requirements of Article 19 of MAR.

Β 

Β 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Stephen KellyΒ 

2

Reason for the notification

a)

Position/status

CEO

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Cirata plc

b)

LEI

213800Y1A75RSC698O04

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares 10p each

Β 

ISIN: JE00B6Y3DV84

b)

Nature of the transaction

Grant of Share options

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

Β 2,400,000

d)

Aggregated information

n/a

e)

Date of the transaction

11 September 2025

f)

Place of the transaction

Outside a trading venue

Β 

Β 


[1] 60-day VWAP 21.93 rounded to 22 pence per share

[2] Issued share capital as at the 3 June 2025 consisted of 126,340,251 ordinary shares of ten pence per share each with voting rights admitted to trading. The Company holds no ordinary shares in Treasury.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
DSHPKBBKKBKDDCD
Date   Source Headline
1st Jun 20267:00 amRNSBlock Listing Return
20th May 20267:00 amRNSResult of AGM
5th May 20267:00 amRNSHolding(s) in Company
23rd Apr 20268:52 amRNSAmendment to Notice of Annual General Meeting
21st Apr 20267:00 amRNSGrant of Awards & PDMR Dealing
14th Apr 20267:00 amRNSTrading Statement
31st Mar 20263:39 pmRNSManagement Changes
31st Mar 20267:00 amRNSPreliminary Results
4th Feb 20268:54 amRNSGrant of Awards & PDMR Dealing
14th Jan 20267:00 amRNSQ4 FY25 Trading Update
19th Dec 20252:50 pmRNSDevOps Final Consideration Received
19th Dec 20252:50 pmRNSDevOps Final Consideration Received
1st Dec 20259:35 amRNSBlock Listing Return
27th Nov 20257:00 amRNSFinancial Conduct Authority Update
17th Nov 20257:00 amRNS$6.7m Multiyear Contract win
27th Oct 202510:05 amRNSNotification of Major Holdings
16th Oct 20257:00 amRNSTrading Statement
13th Oct 20257:00 amRNS$3.1m Multiyear Contract with leading US Insurer
12th Sep 202511:02 amRNSGrant of Awards & PDMR Dealing
10th Sep 20257:00 amRNSNotification of Major Holdings
9th Sep 20258:00 amRNS-RCirata launches new data platform
3rd Sep 20257:00 amRNSInterim results
13th Aug 20257:00 amRNSGrant of Share Options to PDMRs
11th Aug 20257:00 amRNSCompletion of DevOps Divestment
15th Jul 20257:07 amRNSQ2 and H1FY25 Trading Update
30th Jun 20257:01 amRNSHolding(s) in Company
30th Jun 20257:00 amRNS$700K Multiyear Data Integration Contract Renewal
10th Jun 20257:00 amRNSBoard Appointment
3rd Jun 20252:39 pmRNSBlock Listing Return
8th May 20254:47 pmRNSResult of AGM
29th Apr 202511:44 amRNSGrant of Share Options to PDMRs
16th Apr 20257:00 amRNSQ1FY25 Trading Statement
8th Apr 20257:00 amRNSAnnual Report & Notice of AGM
2nd Apr 20253:51 pmRNSNotification of Major Holdings
31st Mar 20257:01 amRNSContract win
31st Mar 20257:00 amRNSPreliminary Results
27th Feb 20257:00 amRNSNew logo in Telecom sector
20th Feb 20257:00 amRNSTotal Voting Rights
20th Jan 20256:29 pmRNSPDMR dealings and Total Voting Rights
9th Jan 20257:00 amRNSQ4FY24 Trading Update
16th Dec 20247:00 amRNSContract Win and FY24 Guidance
13th Dec 20243:46 pmRNSVesting of Restricted Stock & Director Dealings
11th Dec 20247:00 amRNSIssue of Equity
9th Dec 20247:00 amRNSMarvell Contract Renewal
2nd Dec 20243:40 pmRNSBlock Listing Return
1st Nov 20247:00 amRNSGrant of Share Options to PDMRs
24th Oct 20247:00 amRNSPDMR Transactions
9th Oct 20247:00 amRNSQ3 Trading Update and Outlook
2nd Oct 20243:19 pmRNSAmendment of OEM sales partnership with IBM
1st Oct 20247:00 amRNSBoard Appointments

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.